Next-generation sequencing (NGS) has become an increasingly prominent tool in the clinical management of hematologic malignancies, paving the way to improved diagnostics, personalization of treatment, and monitoring of treatment response. Utilized as a tool for whole genome sequencing, exome sequencing, transcriptome sequencing, epigenetic sequencing and more, NGS has become a mainstay in both research and clinical settings.
Hematologic malignancies are a highly heterogeneous group of cancers and, due to the similar clinical presentations of different subtypes, can be hard to accurately diagnose in a short time-frame. NGS has been successfully used to identify novel diagnostic markers in a range of malignancies, and many NGS panels are now commercially available with a turnaround of results in hours or days. These panels enable faster diagnosis and can also be used to guide treatment decisions with targeted therapies. Furthermore, improved treatments resulting in deeper responses have meant that standard methods are no longer sufficiently sensitive in assessing complete remissions. The use of NGS in the monitoring of minimal residual disease (MRD), in particular in multiple myeloma, has been highly impactful in the research field, with many studies demonstrating the value of MRD assessment in prognostication and risk stratification.
This collection aims to collate research on the application of NGS in the clinical setting to improve the detection and diagnosis of hematologic malignancies, to optimize individual treatment and to enhance monitoring of treatment response. Manuscripts on, but not limited to, the following subjects will be welcome:
- The application of NGS for the identification of novel mutations with clinical significance in hematologic malignancies
- Incorporating NGS in the management of hematologic malignancies in clinical practice
- Leveraging NGS to personalize treatment decisions for patients with hematologic malignancies
- Predicting treatment response in hematologic malignancies by using NGS
- NGS in prognostication and risk-stratification for patients with hematologic malignancies
Important Note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
Next-generation sequencing (NGS) has become an increasingly prominent tool in the clinical management of hematologic malignancies, paving the way to improved diagnostics, personalization of treatment, and monitoring of treatment response. Utilized as a tool for whole genome sequencing, exome sequencing, transcriptome sequencing, epigenetic sequencing and more, NGS has become a mainstay in both research and clinical settings.
Hematologic malignancies are a highly heterogeneous group of cancers and, due to the similar clinical presentations of different subtypes, can be hard to accurately diagnose in a short time-frame. NGS has been successfully used to identify novel diagnostic markers in a range of malignancies, and many NGS panels are now commercially available with a turnaround of results in hours or days. These panels enable faster diagnosis and can also be used to guide treatment decisions with targeted therapies. Furthermore, improved treatments resulting in deeper responses have meant that standard methods are no longer sufficiently sensitive in assessing complete remissions. The use of NGS in the monitoring of minimal residual disease (MRD), in particular in multiple myeloma, has been highly impactful in the research field, with many studies demonstrating the value of MRD assessment in prognostication and risk stratification.
This collection aims to collate research on the application of NGS in the clinical setting to improve the detection and diagnosis of hematologic malignancies, to optimize individual treatment and to enhance monitoring of treatment response. Manuscripts on, but not limited to, the following subjects will be welcome:
- The application of NGS for the identification of novel mutations with clinical significance in hematologic malignancies
- Incorporating NGS in the management of hematologic malignancies in clinical practice
- Leveraging NGS to personalize treatment decisions for patients with hematologic malignancies
- Predicting treatment response in hematologic malignancies by using NGS
- NGS in prognostication and risk-stratification for patients with hematologic malignancies
Important Note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
